26 October 2020 

Genetic medicine company Precision NanoSystems has been awarded $13.8m (C$18.2m) in funds to develop a Covid-19 mRNA vaccine candidate from the Canadian Government. The funding is part of the government’s Innovation, Science and Economic Development’s Strategic Innovation Fund aimed at combating Covid-19.

Bharat Biotech has received approval from the Drugs Controller General of India to perform a Phase III clinical trial on its Covaxin Covid-19 vaccine. The approval was given after the regulator evaluated safety and immunogenicity data from Phase I and II clinical trials of the vaccine.

Johnson & Johnson (J&J) has announced plans to resume enrolment for its ENSEMBLE Phase III clinical trial on its subsidiary Janssen‘s Covid-19 vaccine in the US. The trial was paused over an adverse event reported in one of the participants. J&J is resuming the trial after recommendation from the trial’s independent Data Safety and Monitoring Board and after consultation with the U.S. Food and Drug Administration (FDA).

Entos Pharmaceuticals has received $3.8m (C$5m) in funds from the Canadian Government to develop a Covid-19 vaccine. The funds were awarded as part of the government’s National Research Council of Canada Industrial Research Assistance Program aimed at developing domestic Covid-19 vaccines.

The US FDA has approved the restart of Phase III clinical trials on AstraZeneca/University of Oxford AZD1222 Covid-19 vaccine after reviewing safety data related to the trial globally. This trial was paused due to an illness reported in one of the volunteers. Clinical trials on the vaccine will resume across the US, UK, Brazil, South Africa and Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.